Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, John Vetto

Research output: Contribution to journalArticle

2039 Citations (Scopus)

Abstract

We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer. This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice. We treated 25 patients with metastatic cancer in whom standard therapy had failed. Patients received both 1.8 to 18.4 x 1010 autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2. Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma. Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped. Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.

Original languageEnglish (US)
Pages (from-to)1485-1492
Number of pages8
JournalNew England Journal of Medicine
Volume313
Issue number23
StatePublished - 1985
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Interleukin-2
Neoplasms
Melanoma
Neoplasm Metastasis
Leukapheresis
Lung
Lymphokines
Liver
Therapeutics
Renal Cell Carcinoma
Colonic Neoplasms
Animal Models
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. / Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Leitman, S.; Chang, A. E.; Ettinghausen, S. E.; Matory, Y. L.; Skibber, J. M.; Shiloni, E.; Vetto, John.

In: New England Journal of Medicine, Vol. 313, No. 23, 1985, p. 1485-1492.

Research output: Contribution to journalArticle

Rosenberg, SA, Lotze, MT, Muul, LM, Leitman, S, Chang, AE, Ettinghausen, SE, Matory, YL, Skibber, JM, Shiloni, E & Vetto, J 1985, 'Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer', New England Journal of Medicine, vol. 313, no. 23, pp. 1485-1492.
Rosenberg, S. A. ; Lotze, M. T. ; Muul, L. M. ; Leitman, S. ; Chang, A. E. ; Ettinghausen, S. E. ; Matory, Y. L. ; Skibber, J. M. ; Shiloni, E. ; Vetto, John. / Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. In: New England Journal of Medicine. 1985 ; Vol. 313, No. 23. pp. 1485-1492.
@article{f78ee9f64123466db39c9d2efbd464fc,
title = "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer",
abstract = "We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer. This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice. We treated 25 patients with metastatic cancer in whom standard therapy had failed. Patients received both 1.8 to 18.4 x 1010 autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2. Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma. Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped. Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.",
author = "Rosenberg, {S. A.} and Lotze, {M. T.} and Muul, {L. M.} and S. Leitman and Chang, {A. E.} and Ettinghausen, {S. E.} and Matory, {Y. L.} and Skibber, {J. M.} and E. Shiloni and John Vetto",
year = "1985",
language = "English (US)",
volume = "313",
pages = "1485--1492",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

AU - Rosenberg, S. A.

AU - Lotze, M. T.

AU - Muul, L. M.

AU - Leitman, S.

AU - Chang, A. E.

AU - Ettinghausen, S. E.

AU - Matory, Y. L.

AU - Skibber, J. M.

AU - Shiloni, E.

AU - Vetto, John

PY - 1985

Y1 - 1985

N2 - We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer. This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice. We treated 25 patients with metastatic cancer in whom standard therapy had failed. Patients received both 1.8 to 18.4 x 1010 autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2. Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma. Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped. Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.

AB - We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer. This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice. We treated 25 patients with metastatic cancer in whom standard therapy had failed. Patients received both 1.8 to 18.4 x 1010 autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2. Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma. Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped. Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.

UR - http://www.scopus.com/inward/record.url?scp=0022349817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022349817&partnerID=8YFLogxK

M3 - Article

C2 - 3903508

AN - SCOPUS:0022349817

VL - 313

SP - 1485

EP - 1492

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -